[
  {
    "question": "40 years old male with proximal upper and lower limbs weakness associated with tremors and tongue atrophy and fasciculation. On exam he has gynecomastia. What else associated?\nN.B: typical scenario of Kennedy disease.",
    "option_a": "\u2191 serum androgens.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Kennedy disease, also known as spinal and bulbar muscular atrophy (SBMA), is an X\u2010linked disorder caused by a CAG repeat expansion in the androgen receptor gene. It affects males and is characterized by lower motor neuron degeneration combined with endocrine dysfunction, which explains the associated gynecomastia and other signs. The disease is due to a polyglutamine (CAG) expansion in the androgen receptor gene. This expansion causes a toxic gain\u2010of-function effect in the receptor, leading to degeneration of lower motor neurons. The mutated receptor also interferes with normal androgen signaling, contributing to endocrine disturbances such as gynecomastia and altered serum androgen dynamics (with relative increases in circulating androgens or abnormal androgen metabolism). Clinically, patients present with slowly progressive proximal limb weakness, tremors, tongue atrophy with fasciculations, and bulbar signs. The presence of gynecomastia is a major clinical clue that sets Kennedy disease apart from other motor neuron disorders like amyotrophic lateral sclerosis (ALS). Diagnosis is based on clinical features supported by electromyography (EMG) showing denervation, elevated creatine kinase levels, and ultimately confirmed by genetic testing for the CAG repeat expansion in the androgen receptor gene. Differential diagnoses include ALS (which typically lacks endocrine abnormalities) and other neuromuscular disorders. There is no cure for Kennedy disease. Management is supportive and includes physical therapy, speech and swallowing therapies, and symptomatic treatment. Emerging therapies are targeting the toxic androgen receptor pathways. Although androgen manipulation has been explored, there is no established treatment that reverses the hormone abnormalities. (Pregnancy and lactation are not directly relevant since the condition affects males; however, genetic counseling is important for family planning.) Option A (\u2191 serum androgens) is the correct answer because Kennedy disease is associated with endocrine disturbances including an abnormal androgen profile, which helps differentiate it from other motor neuron conditions that lack hormonal involvement. \u2022 Kennedy disease presents with both motor neuron signs and endocrine abnormalities (gynecomastia).  \u2022 It is an X\u2010linked disorder, so it is limited to males.  \u2022 Genetic testing for CAG repeat expansion is confirmatory. Recent studies continue to elucidate the role of toxic androgen receptor accumulation in disease progression. Current clinical trials are investigating agents that may modify receptor toxicity. Although no disease\u2010modifying therapy exists yet, multidisciplinary supportive care remains the mainstay.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "31 years old male has hand grip myotonia, facial weakness, significant facial muscles atrophy, ptosis without ophthalmoplegia and distal arms weakness - what else associated?\nN.B: typical scenario of myotonic dystrophy 1.",
    "option_a": "Diabetes mellitus.",
    "option_b": "Cancer.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonic dystrophy type 1 (DM1) is the most common adult form of muscular dystrophy and is characterized by myotonia, muscle weakness (including facial and distal muscles), and multisystem involvement. DM1 is caused by a CTG trinucleotide repeat expansion in the DMPK gene. The mutant RNA accumulates in the nucleus and disrupts the splicing of various pre-mRNAs, leading to multisystem manifestations including muscular, ocular, cardiac, endocrine, and neurological involvement. Insulin resistance, which can lead to diabetes mellitus, is one of the endocrine abnormalities observed. The typical presentation includes hand grip myotonia, facial muscle atrophy, ptosis (often without ophthalmoplegia), and distal arm weakness. Diabetes mellitus is a recognized systemic association due to insulin resistance, explaining the marked association in the question. Evaluation includes clinical examination (noting myotonia on percussion and grip), electromyography (EMG) showing myotonic potentials, and genetic testing for CTG repeat expansion. Differential diagnoses include other myotonic disorders such as myotonic dystrophy type 2, which has a slightly different phenotype. Management is symptomatic and multidisciplinary. First-line therapies include physical therapy, occupational therapy, and management of endocrine, cardiac, and respiratory issues. For diabetes, standard diabetic management is applied. Specific treatments for myotonia (such as mexiletine) may be considered. In pregnancy and lactation, careful glucose control and cardiac monitoring are advised; medications should be reviewed for safety in pregnancy. Option A (Diabetes mellitus) is correct because insulin resistance and subsequent diabetes are well-documented endocrine manifestations of myotonic dystrophy type 1. Option B (Cancer) is not a typical association with DM1. \u2022 Myotonic dystrophy type 1 features myotonia that can be elicited with percussion. \u2022 Look for multisystem involvement: cataracts, insulin resistance, and arrhythmias are common. \u2022 Genetic testing confirms the diagnosis by identifying the CTG repeat expansion. Recent research emphasizes a multidisciplinary approach in DM1 management, with new therapeutic avenues targeting RNA splicing abnormalities under investigation. Guidelines now underscore the need for monitoring cardiac and endocrine complications longitudinally.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Typical case of young lady with diurnal proximal muscle weakness with dysarthria and tongue fasciculations. What is the likely diagnosis?",
    "option_a": "LEMS.",
    "option_b": "Anti Musk MG.",
    "option_c": "Anti AchR MG.",
    "option_d": "Botulism.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder. There are subtypes based on the target antibody. Anti-MuSK MG is a distinct subgroup characterized primarily by antibodies against muscle-specific kinase, leading to a pattern of muscle weakness that often involves bulbar, facial, and neck muscles. In anti-MuSK MG, antibodies target MuSK, a protein involved in the clustering of acetylcholine receptors at the neuromuscular junction. This disruption leads to impaired neuromuscular transmission. Unlike typical anti-AChR MG, anti-MuSK MG can be associated with muscle atrophy, particularly of bulbar muscles, and sometimes a clinical picture that emphasizes proximal and bulbar weakness. The patient\u2014a young lady with diurnal proximal muscle weakness, dysarthria, and signs affecting the tongue\u2014is consistent with an MG variant. The predominance of bulbar symptoms (dysarthria) and involvement of tongue muscles (which in anti-MuSK MG may show atrophy that could be interpreted as fasciculations) point toward anti-MuSK MG, even though true fasciculations are more classically a sign of lower motor neuron disease. The diurnal variability is a hallmark of myasthenia gravis. Diagnosis involves serological testing for specific antibodies (anti-MuSK versus anti-AChR), electrodiagnostic studies demonstrating decremental response on repetitive nerve stimulation, and sometimes single fiber EMG. Differential diagnoses include Lambert-Eaton myasthenic syndrome (which has autonomic involvement and improves with repeated activity), typical anti-AChR MG (often with ocular signs), and botulism (which has a different clinical course and additional features such as fixed dilated pupils). First-line management for MG generally includes acetylcholinesterase inhibitors (e.g., pyridostigmine), but patients with anti-MuSK MG often show a variable response to these agents. Immunosuppressive therapy (such as corticosteroids and azathioprine) is frequently required and can be considered first-line in anti-MuSK cases following initial symptomatic treatment. In severe cases, plasmapheresis or IVIG may be used. Pregnancy and lactation considerations include selecting immunosuppressants that are safer in pregnancy (for instance, prednisone and azathioprine are generally considered when needed, while mycophenolate mofetil is contraindicated), and close monitoring is essential during the peripartum period. Option A (LEMS) is less likely because LEMS often has prominent autonomic dysfunction and a different response pattern. Option C (Anti-AChR MG) is the most common form of MG but typically presents with ocular involvement, which is not highlighted here. Option D (Botulism) has a different clinical trajectory. Thus, Option B (Anti-MuSK MG) is the most consistent with predominant bulbar symptoms in this scenario. \u2022 Anti-MuSK MG should be suspected in patients with prominent bulbar symptoms and minimal ocular involvement. \u2022 Muscle atrophy, especially in the tongue and facial muscles, is more common in anti-MuSK MG. \u2022 Diurnal fluctuation of weakness is a key feature in all forms of MG. Recent guidelines and research emphasize tailored immunotherapy for anti-MuSK MG, including early use of corticosteroids and consideration of rituximab in refractory cases. Outcome studies and controlled trials continue to refine the optimal management strategy for this subgroup.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has difficulty blowing the air in mouth, asymmetrical winging and right foot drop. Diagnosis?",
    "option_a": "FSHD",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscular dystrophy characterized by progressive weakness of the facial, scapular, and humeral muscles, often with an asymmetric distribution. FSHD is most commonly associated with a deletion in the D4Z4 repeat array on chromosome 4q35, which leads to inappropriate expression of the DUX4 gene. The toxic gain-of-function effect from DUX4 expression results in muscle cell degeneration. The pattern of muscle involvement is typically descending and asymmetrical. Patients with FSHD often present with difficulty with facial movements (such as blowing air due to weakness of the orbicularis oris), scapular winging that is asymmetric, and in some cases lower extremity involvement manifesting as foot drop. The asymmetry is a key distinguishing feature compared to other muscular dystrophies. Diagnosis is made by clinical evaluation and confirmed with genetic testing demonstrating the characteristic deletion in the D4Z4 region. Differential diagnoses include other muscular dystrophies (like limb-girdle muscular dystrophy), myotonic dystrophy, and even motor neuron diseases (which usually have different patterns and additional signs such as fasciculations in ALS). There is no cure for FSHD; management is supportive. Physical therapy, occupational therapy, and the use of orthotic devices (such as for foot drop) are mainstays. Pain management and surgical correction (if necessary) may be considered. Genetic counseling is important given its autosomal dominant inheritance. In pregnancy and lactation, multidisciplinary management is advised although the disease does not typically worsen during pregnancy, attention to rehabilitation needs is important. Option A (FSHD) is correct as it best fits the clinical picture of facial weakness (difficulty blowing), asymmetric scapular winging, and distal lower limb involvement (foot drop). There are no alternative options better suited to this pattern. \u2022 FSHD typically has an asymmetric pattern of involvement. \u2022 Facial weakness with difficulty performing tasks like blowing air is a high-yield clinical clue. \u2022 Scapular winging in FSHD is characteristically asymmetric. Current research is focused on gene modulation therapies and further characterization of the DUX4 pathogenic pathway. There is active investigation into potential molecular targets to slow disease progression, although management remains largely supportive and multidisciplinary.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of recurrent painless multifocal mononeuropathies at the common compression sites. PMP22 deletion was detected. What is the expected biopsy findings?",
    "option_a": "Sausage shaped C Tamaculae.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) is a genetic disorder that leads to recurrent, painless mononeuropathies at sites of nerve compression. The underlying genetic defect is a deletion in the PMP22 gene, which encodes a protein essential for myelin stability in the peripheral nervous system. The PMP22 deletion results in abnormal myelin formation with a predisposition to focal demyelination and remyelination. These cycles produce focal thickenings of the myelin (called tomacula) which are histologically recognized as \u2018sausage\u2010shaped\u2019 or nodular enlargements. These areas are more vulnerable to compression and mechanical stress, leading to the clinical episodes seen in HNPP. Patients commonly present with recurrent episodes of focal nerve deficits at predisposed entrapment sites (e.g., ulnar groove at the elbow, peroneal head at the knee) that are characteristically painless. The nerve biopsy in HNPP reveals tomacula, which are pathognomonic features of the disease. The diagnosis is based on clinical history, nerve conduction studies showing focal slowing or conduction block at common compression sites, and confirmation with genetic testing for the PMP22 deletion. Differential diagnoses include chronic inflammatory demyelinating polyneuropathy (CIDP) \u2013 which shows more diffuse demyelination with inflammatory infiltrates \u2013 and entrapment mononeuropathies due to mechanical causes. Nerve biopsy, while not routinely required, may be used to distinguish HNPP (tomacula formation) from other demyelinating neuropathies. Management is largely supportive. Patients are advised to avoid repetitive nerve injury and compression. Physical therapy and ergonomic adaptations can help reduce the frequency of episodes. There is no curative therapy. During pregnancy and lactation, similar conservative management applies. Genetic counseling is recommended for families, and while symptomatic treatment is the mainstay, managing comorbid conditions is vital. Option A stated 'Sausage shaped C Tamaculae', which is a colloquial description for the tomacular formations in the myelin, making it the correct answer. Other options, though not listed, would likely involve findings not typical for HNPP such as inflammatory infiltrates or onion-bulb formations seen in other demyelinating disorders. 1. Tomacula (sausage\u2010shaped myelin thickenings) are pathognomonic for HNPP. 2. HNPP is due to PMP22 deletion, contrasting with PMP22 duplication in CMT1A. 3. Episodes are typically painless and occur at common nerve compression sites. Recent guidelines emphasize the role of genetic testing (via multiplex ligation-dependent probe amplification or similar methods) to confirm the PMP22 deletion, reducing the need for invasive nerve biopsy. Ongoing research focuses on the molecular mechanisms of PMP22-related myelin instability and potential neuroprotective strategies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of recurrent painless multifocal mononeuropathies at the common compression sites. HNPP disease was suspected. What is the most important genetic test?",
    "option_a": "PMP 22 deletion.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "HNPP is primarily a genetic disorder caused by a deletion of the PMP22 gene. Genetic confirmation is crucial for diagnosis and counseling. This question focuses on the pivotal role of identifying the PMP22 deletion. The deletion of the PMP22 gene results in abnormal myelin structure with areas of focal thickening (tomacula). This abnormality predisposes nerves to increased mechanical vulnerability, resulting in recurrent, pressure-induced neuropathies. Clinically, HNPP presents as recurrent episodes of nerve palsies that are typically painless and occur at sites susceptible to compression. The genetic test for PMP22 deletion directly relates to the underlying cause and confirms the diagnosis in patients with corresponding clinical and electrodiagnostic findings. The diagnostic work-up includes a thorough clinical exam, nerve conduction studies demonstrating conduction slowing at pressure points, and confirmatory genetic testing for the PMP22 deletion. Differential diagnosis includes entrapment neuropathies from mechanical causes and inflammatory neuropathies, but these conditions will not show the specific PMP22 deletion. There is no curative treatment for HNPP. Management includes avoidance of nerve compression, physical therapy, and education about the condition. Genetic counseling is recommended. During pregnancy and lactation, management remains supportive and focused on lifestyle modifications to reduce nerve injury. Option A, which is 'PMP22 deletion', is correct because the detection of PMP22 gene deletion is the most important genetic test for the diagnosis of HNPP. Other tests would not target the causative genetic mutation. 1. PMP22 deletion is pathognomonic for HNPP. 2. Genetic testing is essential for confirming the diagnosis in patients with recurrent, painless mononeuropathies. 3. Differential diagnosis includes other forms of neuropathy, but genetic testing distinguishes HNPP. Current guidelines recommend genetic testing using techniques such as MLPA or array comparative genomic hybridization for definitive diagnosis of HNPP. Recent studies have improved the understanding of the genotype-phenotype correlations in PMP22-related disorders.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "baby, hx of hypotonia, cardiomegaly and macroglossia CK high\n\nWhat is the diagnosis",
    "option_a": "Acid maltase (pompe)",
    "option_b": "Phosphofructokinase",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical picture of a baby with hypotonia, cardiomegaly, macroglossia, and elevated creatine kinase (CK) is classic for Pompe disease (acid maltase deficiency). This metabolic disorder is due to a deficiency of the lysosomal enzyme acid alpha-glucosidase. In Pompe disease, mutations in the gene encoding acid maltase (acid alpha-glucosidase) lead to lysosomal glycogen accumulation. In infants, this results in progressive muscle weakness, cardiomegaly from glycogen deposition in the heart, and other systemic manifestations such as macroglossia. Infantile Pompe disease typically presents between birth and the first few months of life with profound hypotonia, feeding difficulties, cardiomegaly, and respiratory distress. The elevated CK is reflective of muscle damage due to glycogen accumulation in cardiac and skeletal muscles. Diagnosis is confirmed by measuring acid alpha-glucosidase enzyme activity in blood or fibroblasts and can be supplemented with molecular genetic testing. Differential diagnoses include other glycogen storage diseases (e.g., Danon disease) and metabolic myopathies; however, the combination of cardiomegaly, macroglossia, and hypotonia strongly favors Pompe disease. The current standard of care is enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase, which has been shown to improve survival and cardiac function in infants. Supportive care including respiratory and nutritional support is also essential. For pregnant or lactating patients who are carriers or at risk, genetic counseling is important, and ERT safety in pregnancy is evaluated on a case-by-case basis; current data are limited but generally suggest careful monitoring if treatment is needed. Option A is 'Acid maltase (Pompe)' and it is the correct diagnosis in this clinical scenario. Other options such as phosphofructokinase deficiency would not typically present with cardiomegaly and macroglossia in the infantile period. 1. Classic infantile Pompe disease presents with hypotonia, cardiomegaly, and macroglossia. 2. Elevated CK is a common laboratory finding. 3. Early initiation of enzyme replacement therapy is crucial to improve outcomes. Recent studies and guideline updates have highlighted the benefits of early diagnosis and intervention with ERT. There is ongoing research into improved therapeutic strategies including chaperone therapies and gene therapy for Pompe disease.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Young male with hx of one side UL weakness progressive over 5 years then become started\nExamination involve all hand muscles with spearing brachioradilaus\n\nWhat is the other associated features:",
    "option_a": "nalysis provided clarified that there are no additional associated features such as upper motor neuron signs, sensory deficits, bulbar involvement, bilateral early involvement, or rapid progression to respiratory failure. Thus, the correct answer is 'None' (marked as Option A), signifying that this focal anterior horn cell disorder lacks these associated features. Each of the common incorrect options mentioned in the analysis is not seen in focal anterior horn cell pathologies like Hirayama disease.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a young male with a progressive unilateral upper limb weakness affecting all hand muscles, with sparing of the brachioradialis. This clinical pattern is characteristic of a focal anterior horn cell disorder such as monomelic amyotrophy (also known as Hirayama disease). Focal anterior horn cell diseases, like Hirayama disease, involve the selective degeneration of the lower motor neurons in the anterior horn of the spinal cord. The preservation or relative sparing of certain muscles (such as the brachioradialis) is a distinct clinical hallmark, likely due to differences in the innervation patterns of the involved muscles. Patients typically present with a slowly progressive, unilateral weakness and atrophy of the hand and forearm muscles. Importantly, there are no upper motor neuron signs (such as brisk reflexes or spasticity), no sensory deficits, and bulbar muscles are not involved. This distinguishes it from other motor neuron diseases like ALS. The diagnosis is primarily clinical, supported by electromyography (EMG) findings that reveal neurogenic changes in the affected muscles. Differential diagnoses include amyotrophic lateral sclerosis (ALS), which would have both upper and lower motor neuron signs, and peripheral nerve entrapments or multifocal neuropathies which may manifest with sensory involvement. Management is generally conservative, focusing on physical therapy, occupational therapy, and the avoidance of activities that might exacerbate the condition. In some cases, a cervical collar may be used to prevent neck flexion which is thought to contribute to disease progression. There is no role for immunosuppressive or other systemic therapies. In pregnancy and lactation, treatment remains supportive with an emphasis on maintaining function and preventing injury. The option analysis provided clarified that there are no additional associated features such as upper motor neuron signs, sensory deficits, bulbar involvement, bilateral early involvement, or rapid progression to respiratory failure. Thus, the correct answer is 'None' (marked as Option A), signifying that this focal anterior horn cell disorder lacks these associated features. Each of the common incorrect options mentioned in the analysis is not seen in focal anterior horn cell pathologies like Hirayama disease. 1. Hirayama disease typically presents with unilateral hand and forearm weakness with sparing of the brachioradialis. 2. The absence of UMN signs or sensory deficits helps differentiate it from degenerative motor neuron diseases like ALS. 3. It is a slowly progressive and usually benign condition. Current research emphasizes the importance of early diagnosis through careful clinical evaluation and EMG studies. Recent guidelines recommend conservative management, and studies are exploring the benefits of cervical collar use to minimize disease progression. Advances in imaging have further elucidated the dynamic changes in the cervical spine related to this condition.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "female with hx of neuropathic ulcer, Testing for PMP22 deletion and duplication -ve What is the gene",
    "option_a": "IK",
    "option_b": "T",
    "option_c": "is blank, making D the only viable and correct answer.",
    "option_d": "SPLECT",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "This question deals with a hereditary neuropathy presenting with neuropathic ulcers. In many inherited neuropathies such as Charcot\u2010Marie\u2010Tooth disease type 1A, a duplication (or deletion in the case of HNPP) of the PMP22 gene is responsible. When PMP22 abnormalities are excluded by testing, one must consider other genetic causes of a neuropathy that can lead to loss of sensation and trophic ulceration. Hereditary Sensory and Autonomic Neuropathy (HSAN), particularly type I, is a well\u2010known cause of neuropathic ulcers due to mutations in genes such as SPTLC1 (often misrepresented in exam options as \u201cSPLECT\u201d). Mutations in the SPTLC1 gene lead to abnormal sphingolipid metabolism. This disruption results in the accumulation of neurotoxic metabolites that damage small sensory fibers, leading to progressive loss of pain and temperature sensation. Loss of protective sensation in the distal extremities predisposes patients to repeated trauma and ulcer formation. Patients, especially young females, may present with painless neuropathic ulcers as a result of impaired nociception. The negative findings on PMP22 deletion/duplication testing prompt consideration of alternative genetic forms of neuropathy, such as HSAN type I, which directly explains the clinical findings. The evaluation should start with a detailed clinical history and neurological exam. When a common gene (PMP22) is ruled out, further genetic testing targeting HSAN-related genes (e.g., SPTLC1) is indicated. Differential diagnoses include diabetic neuropathy, other hereditary neuropathies (e.g., CMT variants with MPZ or GJB1 mutations), and acquired causes of small fiber neuropathy. The presence of a familial pattern and early onset should raise suspicion for a hereditary etiology. There is no cure for HSAN; management focuses on symptomatic treatment and complication prevention. Protecting the feet with proper footwear, regular podiatric examinations, and patient education are crucial. Pain management and wound care are important, and referrals to specialized centers for genetic counseling may be considered. In pregnancy and lactation, management remains supportive, with careful attention to wound care and prevention of secondary infections while using medications with proven safety profiles. Option A (IK) and Option B (T) do not correspond to recognized gene mutations in hereditary sensory neuropathy. Option D \u2013 \u2018SPLECT\u2019 \u2013 although a nonstandard representation, appears to be a reference to the SPTLC1 gene mutation, which is consistent with a diagnosis of HSAN type I. Option C is blank, making D the only viable and correct answer. 1. Negative PMP22 testing in a patient with neuropathic ulcers should prompt evaluation for alternative genetic neuropathies like HSAN. 2. Mutations in SPTLC1, which affect sphingolipid metabolism, are a known cause of HSAN type I leading to ulcerations due to loss of pain sensation. Recent genetic studies and updated reviews emphasize a broader panel for genetic testing in hereditary neuropathies once PMP22 abnormalities are excluded. Next-generation sequencing often identifies SPTLC1 mutations in patients with clinical features of HSAN type I, supporting earlier targeted genetic investigations.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Filipino male pt came with hx of generalized weakness upon waking (Repeated many time in the common) What to order",
    "option_a": "potassium level",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario is a classic description of an episodic muscle weakness presentation, frequently seen in periodic paralyses. Many of these conditions present with transient episodes of weakness, often upon waking due to diurnal variations and triggers such as sleep or rest following exertion. Hypokalemic periodic paralysis is caused by ion channel mutations (most commonly in calcium or sodium channels) that result in abnormal membrane excitability. A shift of potassium into cells during an attack leads to a low serum potassium level and transient muscle inexcitability. Generalized muscle weakness in the morning is characteristic. Patients often experience episodes of weakness that may resolve spontaneously or respond to electrolyte correction. Evaluating serum potassium during an acute episode is crucial for diagnosis. The work-up includes measurement of serum electrolytes, especially potassium, during an attack. Differential diagnoses include thyrotoxic periodic paralysis (where thyroid function tests are indicated) and other neuromuscular disorders such as myasthenia gravis or metabolic myopathies. Timely potassium measurement helps distinguish hypokalemic periodic paralysis from these conditions. Acute attacks are managed by careful potassium supplementation while monitoring for rebound hyperkalemia. Prophylactic measures include lifestyle modifications, dietary changes (avoiding carbohydrate-rich meals), and in some cases a carbonic anhydrase inhibitor like acetazolamide. In pregnant or lactating women, treatment is tailored with attention to potassium replacement and careful use of adjunctive therapies, with consultation from maternal-fetal medicine when needed. Option A (checking the potassium level) is the correct initial test given the suspected hypokalemic periodic paralysis. The lack of alternative options or tests in the other choices makes A the clear and appropriate first step in the work-up during an episode of generalized weakness. 1. Always check serum potassium during an episode of periodic paralysis to confirm a diagnosis and guide acute management. 2. Morning weakness in an otherwise healthy individual with episodic symptoms strongly suggests periodic paralysis. Recent guidelines reinforce the importance of electrolyte measurement during an acute attack and suggest that early identification and management of hypokalemic periodic paralysis can prevent complications. Additionally, genetic testing may be considered for familial cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "55 y/o male, hx of lower limbs weakness for days, initially started with numbness and tingling, days later started to involve upper limbs, associated with hyperhydrosis in lbs and involve face And Hx of epigastric pain. Examination bilateral LL weakness Hx of influenza vaccine 2 weeks prior to onset\n\nWhat is the diagnosis",
    "option_a": "AIP",
    "option_b": "AIDP",
    "option_c": "Acute spinal",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a subacute, ascending weakness that began in the lower limbs, later involving the upper limbs with facial involvement and autonomic signs (hyperhidrosis). The recent history of an influenza vaccine serves as a well\u2010recognized trigger for immune-mediated neuropathies, particularly Guillain\u2013Barr\u00e9 syndrome (GBS). AIDP (acute inflammatory demyelinating polyradiculoneuropathy) is the most common variant of GBS. AIDP is an immune-mediated disorder characterized by demyelination of peripheral nerves. An antecedent infection or vaccination triggers an aberrant immune response, leading to cross-reactive antibodies that target peripheral nerve myelin. This results in conduction slowing, neurological deficits, and sometimes autonomic disturbances. Patients typically present with rapidly progressive, symmetric, ascending muscle weakness, which may include facial weakness. Autonomic dysfunction (e.g., hyperhidrosis, blood pressure instability) is common. The antecedent event (influenza vaccination 2 weeks prior) is a typical clinical clue supporting AIDP. Diagnosis is based on clinical presentation, supported by nerve conduction studies showing demyelination and cerebrospinal fluid analysis demonstrating albumin\u2013cytological dissociation. Differential diagnoses include acute intermittent porphyria (which usually has prominent abdominal pain and psychiatric symptoms) and acute spinal cord syndromes (which typically produce a sensory level and hyperreflexia). First-line treatment for AIDP includes intravenous immunoglobulin (IVIG) or plasmapheresis, both of which are considered safe in pregnancy and lactation. Supportive care, including monitoring respiratory function and autonomic stability, is crucial. Early treatment is associated with a better prognosis. Option B (AIDP) is the most appropriate diagnosis given the clinical context. Option A (AIP) is less likely because although it can present with abdominal pain and neuropathy, it typically affects young women and does not follow a post-vaccination pattern. Option C (\u2018Acute spinal\u2019) would suggest a localized spinal cord lesion, which is inconsistent with the diffuse, ascending involvement and facial weakness observed here. 1. A history of a recent vaccination or infection is a key detail that can point toward Guillain\u2013Barr\u00e9 syndrome. 2. The presence of ascending weakness with autonomic symptoms should prompt urgent evaluation for AIDP. Recent guidelines by neurology societies emphasize early recognition and treatment of GBS with IVIG or plasmapheresis. Studies continue to support the safety of IVIG during pregnancy, with monitoring for any potential complications.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "young male, hx of generalized weakness, spring face and repository Examination: hypo reflexia Came to ER, received K supplements, later he repeated same attacks weekly K level 2.6 (low) What is the most accurate management",
    "option_a": "Acetazolamide",
    "option_b": "Mexiltine",
    "option_c": "Spironolactone",
    "option_d": "Daily potassium dose",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case outlines a young male with recurrent episodes of generalized weakness associated with documented hypokalemia (K level of 2.6 mEq/L). This clinical picture is characteristic of hypokalemic periodic paralysis, a disorder of muscle excitability related to ion channel dysfunction. Hypokalemic periodic paralysis is typically due to mutations affecting voltage-gated ion channels (commonly calcium or sodium channels) in skeletal muscle. These mutations lead to an abnormal shift of potassium into the cells during trigger events such as rest after exercise or high-carbohydrate meals, resulting in transient muscle inexcitability during episodes. Patients experience episodic weakness that may be precipitated by various triggers. The recurrent, self-limited episodes combined with low serum potassium measurements firmly support the diagnosis of a channelopathy leading to periodic paralysis. Diagnosis is confirmed by demonstrating hypokalemia during an attack. Differential diagnoses include thyrotoxic periodic paralysis (which would also require evaluation of thyroid function tests) and other metabolic or neurologic causes of episodic weakness. A detailed family history and, if indicated, genetic testing can help differentiate familial periodic paralysis from secondary causes. Acute attacks are managed with careful potassium supplementation. For prophylaxis, carbonic anhydrase inhibitors such as acetazolamide are the first-line treatment. This medication reduces the frequency and severity of episodes by stabilizing ion channel function and reducing the propensity for potassium shifts. In pregnancy and lactation, acetazolamide is classified as a Category C medication; its use should be weighed carefully against potential risks, with alternative prophylactic approaches considered if the risk\u2013benefit profile is unfavorable. Option A (Acetazolamide) is the correct choice for long-term prophylactic management of hypokalemic periodic paralysis. Option D (daily potassium dose) may help acutely but is not the best strategy for preventing recurrent episodes. Option B (Mexiletine) is more commonly used for myotonic disorders rather than periodic paralysis, and Option C (Spironolactone) is not standard management for this condition. 1. In hypokalemic periodic paralysis, prophylactic treatment with acetazolamide can effectively reduce the frequency and severity of attacks. 2. Always distinguish between acute management (potassium supplementation) and chronic prophylaxis in channelopathies. Recent studies and consensus guidelines continue to support acetazolamide as a first-line prophylactic agent in familial hypokalemic periodic paralysis. Ongoing research into the genetic basis of the disease may further tailor individual management strategies, especially in the context of familial screening and personalized treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "50s male, hx of progressive lower limb weakness with tingling and numbness and numbness for 3 months, then become static, later he had sudden Rt foot drop. Examination weakness with areflexia",
    "option_a": "Lambert",
    "option_b": "CIDP",
    "option_c": "MMN",
    "option_d": "ALS",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is an acquired, immune\u2010mediated peripheral neuropathy that typically presents with a combination of motor and sensory deficits developing over at least 8 weeks. Patients often have a chronic or relapsing course with proximal and distal weakness accompanied by paresthesias. CIDP is thought to be mediated by autoimmune mechanisms that target the myelin sheath of peripheral nerves. T\u2010cells and macrophages infiltrate the nerves leading to demyelination and, in some cases, secondary axonal damage. The resultant conduction slowing and conduction block account for the clinical deficits observed. In this 50-year-old man, the progressive lower limb weakness with tingling and numbness, areflexia on exam, and the sudden onset of right foot drop are consistent with a demyelinating process affecting both motor and sensory fibers. The static phase following the initial progression may indicate a plateau in the inflammatory activity, with subsequent focal exacerbation (foot drop) due to a conduction block. Diagnosis is generally confirmed with nerve conduction studies showing demyelinating features such as slowed conduction velocity, prolonged distal latencies, and multifocal conduction blocks. Differential diagnoses include Guillain\u2013Barr\u00e9 syndrome (which has an acute/subacute onset), Multifocal Motor Neuropathy (purely motor, typically asymmetric, and without significant sensory loss), and ALS (which is characterized by combined UMN and LMN signs without sensory involvement). First-line therapy for CIDP includes corticosteroids, intravenous immunoglobulin (IVIG), and plasmapheresis in refractory cases. For pregnancy and lactation, IVIG is favored due to its established safety profile. Corticosteroids can be used with careful monitoring of potential fetal effects, and plasmapheresis may be considered when indicated. Option A (Lambert\u2013Eaton syndrome) typically presents with proximal muscle weakness and is often paraneoplastic. Option C (Multifocal Motor Neuropathy) involves purely motor deficits. Option D (ALS) shows combined UMN/LMN findings without sensory deficits. Option B (CIDP) accurately reflects the combination of sensory and motor involvement with a chronic course, making it the correct choice. 1. CIDP is one of the few neuropathies that presents with both motor and sensory deficits along with areflexia. 2. Electrophysiological studies are essential for confirming demyelination. 3. Early treatment with immunomodulatory therapies can modify the disease course. Recent guidelines endorse early diagnosis and treatment with IVIG or corticosteroids to prevent irreversible nerve damage. Ongoing research focuses on optimizing dosing strategies and evaluating newer immunotherapeutics to improve long-term outcome in CIDP.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "23 y/o male hx of respiratory failure, cerebral aneurysm,\n\nEMG : Mytonia without clinical mytonia\n\nWhat is the diagnosis",
    "option_a": "Pompe",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a metabolic myopathy caused by an enzyme deficiency resulting in glycogen accumulation within lysosomes. The adult-onset form typically presents with muscle weakness, respiratory insufficiency, and subtle electrophysiological abnormalities. The deficiency of acid alpha-glucosidase leads to the accumulation of glycogen within lysosomes of muscle fibers. This glycogen overload disrupts normal muscle function and can affect both skeletal and respiratory muscles. Uncommonly, glycogen deposition can be associated with vascular abnormalities, such as cerebral aneurysms, possibly due to similar deposition in vascular smooth muscle. The 23-year-old patient\u2019s history of respiratory failure along with the presence of a cerebral aneurysm are notable. Additionally, the EMG findings of myotonia (indicated by myotonic discharges) in the absence of overt clinical myotonia are a recognized, albeit less common, feature of Pompe disease in adults. This pattern, sometimes referred to as 'silent myotonia,' distinguishes it from other myotonic disorders. Diagnosis is typically confirmed via enzyme assay demonstrating reduced acid alpha-glucosidase activity, genetic testing for mutations in the GAA gene, and, when necessary, muscle biopsy showing glycogen accumulation. Differential diagnoses include myotonic dystrophy (which usually presents with clinical myotonia and multisystem involvement) and other metabolic myopathies. The unique combination of respiratory failure and subtle myotonic discharges favor Pompe disease. The management of Pompe disease centers on enzyme replacement therapy (ERT) with alglucosidase alfa, which can slow progression of muscle weakness and improve respiratory function. Supportive care including respiratory support and physiotherapy are important. In pregnancy and lactation, the use of ERT should involve a careful risk-benefit assessment, though emerging data suggest that with close monitoring it may be offered when necessary. Option A (Pompe disease) is selected because the combination of respiratory failure, cerebral aneurysm, and the presence of EMG myotonic discharges without overt clinical myotonia is most consistent with this disorder. Other potential options (not listed) such as myotonic dystrophies would typically present with evident clinical myotonia and additional systemic features. 1. Adult-onset Pompe disease can present with predominant respiratory involvement and subtle EMG findings. 2. Myotonic discharges on EMG in Pompe disease may not correlate with clinical myotonia. 3. Always consider metabolic myopathies in young patients with unexplained respiratory failure. Recent trials have reinforced the benefits of early ERT in altering the disease course of late-onset Pompe disease. Advances in genetic screening and enzyme assays have improved diagnostic accuracy, and current research is focused on optimizing ERT regimens and exploring adjunctive therapies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "pt with urinary incontinnccae and sx suggesting autonomic with painful neuropathy NCS : axonal neuropathy with CTS Investigation :",
    "option_a": "Abdominal fat pad",
    "option_b": "electrophoresis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Systemic amyloidosis is a condition characterized by the abnormal deposition of amyloid proteins in various tissues including nerves, the heart, kidneys, and soft tissues. When the peripheral nervous system is involved, patients can develop a painful length-dependent axonal neuropathy often accompanied by autonomic dysfunction. Amyloid deposits, composed of misfolded proteins, accumulate in the extracellular space of affected tissues. In the peripheral nerves, these deposits tend to affect small fibers leading to painful neuropathy and can involve autonomic fibers, causing symptoms such as urinary incontinence. Deposition in specific anatomical regions, like the wrist, can lead to carpal tunnel syndrome. The presentation of painful neuropathy with autonomic features (urinary incontinence) and nerve conduction studies showing axonal neuropathy along with carpal tunnel syndrome is highly suggestive of an amyloid neuropathy. This constellation of findings should prompt evaluation for systemic amyloidosis. The diagnosis is generally confirmed by tissue biopsy demonstrating amyloid deposition. An abdominal fat pad biopsy is a widely used, minimally invasive test with good diagnostic yield. Differential considerations include diabetic neuropathy, chronic inflammatory demyelinating polyneuropathy (CIDP), and other causes of small-fiber neuropathy; however, the combination of autonomic features, painful neuropathy, and CTS is more typical of amyloidosis. Treatment is guided by the type of amyloidosis. For AL amyloidosis, chemotherapy to address the underlying plasma cell dyscrasia is the mainstay, while ATTR amyloidosis may be managed with liver transplantation or pharmacologic stabilizers (e.g., tafamidis). Symptomatic treatments for neuropathic pain and autonomic dysfunction are also used. In the context of pregnancy and lactation, management requires a multidisciplinary approach; many chemotherapeutic agents are contraindicated in pregnancy, so careful risk\u2013benefit assessment and alternative supportive measures are essential. Option A (Abdominal fat pad biopsy) is a well-recognized diagnostic procedure for systemic amyloidosis because of its minimally invasive nature and reasonable sensitivity. Option B (electrophoresis) can help detect monoclonal gammopathy in AL amyloidosis but may not be diagnostic on its own. Thus, as an investigative step to obtain tissue confirmation, Option A is most appropriate. 1. Amyloidosis should be suspected in patients with a painful neuropathy that includes autonomic dysfunction and carpal tunnel syndrome. 2. Abdominal fat pad biopsy is a simple, minimally invasive test with good diagnostic yield in amyloidosis. 3. Early diagnosis is critical as treatment can prevent irreversible organ damage. Current consensus guidelines promote early tissue diagnosis in suspected amyloidosis cases. Novel therapies targeting amyloid fibril formation and deposition are under investigation, and recent data continue to refine strategies for differentiating AL versus ATTR subtypes, which is essential for targeted treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "case of pt with cramp and stiffness that relive with movements, same hx in the father Diagnosis :",
    "option_a": "Thamson",
    "option_b": "Paramytonia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Thomsen disease is a form of myotonia congenita, an inherited skeletal muscle channelopathy characterized by delayed muscle relaxation after contraction. It is inherited in an autosomal dominant fashion and is associated with muscle stiffness that typically improves with repeated movement (the warm-up phenomenon). Mutations in the CLCN1 gene, which encodes the chloride channel in muscle membranes, lead to a reduced chloride conductance. This results in hyperexcitability of the muscle fibers and the generation of myotonic discharges. In the dominant form (Thomsen disease), the mutation leads to milder symptoms compared with the recessive (Becker) variant. The patient\u2019s presentation with cramps and stiffness that improve with movement is highly characteristic of myotonia congenita. The fact that a similar history is present in the father strongly supports an autosomal dominant inheritance pattern, which is typical of Thomsen disease as opposed to paramyotonia congenita, where symptoms often worsen with repeated use or cold exposure. Diagnosis is primarily clinical, supported by electromyography (EMG) which demonstrates myotonic discharges. Differential diagnoses include paramyotonia congenita (which is aggravated by cold and repeated activity) and myotonic dystrophy (which is multisystemic and typically has additional features such as cataracts and cardiac conduction defects). Management is largely symptomatic. Mexiletine, a sodium channel blocker, is considered first-line therapy to reduce myotonia. Other agents such as carbamazepine may be used if mexiletine is contraindicated. During pregnancy and lactation, mexiletine is generally avoided due to potential harm to the fetus; dose adjustments or alternative treatments should be considered in these cases with careful risk\u2013benefit analysis. Option A (Thomsen disease) is correct because it aligns with an autosomal dominant pattern and the characteristic improvement of stiffness with movement (warm-up phenomenon). Option B (Paramyotonia) is typically associated with paradoxical myotonia that worsens with repeated use or exposure to cold, making it an incorrect choice in this scenario. 1. The warm-up phenomenon is a hallmark of myotonia congenita (Thomsen disease). 2. A positive family history is a key clue in distinguishing hereditary myotonic disorders. 3. EMG is a supportive diagnostic tool, demonstrating characteristic myotonic discharges even when clinical myotonia may be subtle. Recent clinical studies continue to support mexiletine as the treatment of choice for symptomatic relief in myotonia congenita. Genetic testing has become increasingly accessible, aiding in the definitive diagnosis and counseling of affected families. Ongoing research is focused on novel agents that may better target the ion channel dysfunction underlying the disorder.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "case hypokalemic periodic paralysis\nWhat help in diagnosis",
    "option_a": "Long exercise test",
    "option_b": "Short exercise test",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Hypokalemic periodic paralysis is a channelopathy characterized by episodic muscle weakness triggered by abnormal shifts in potassium levels. Electrophysiologic assessments, such as the long exercise test, evaluate changes in muscle membrane excitability and help to identify the defect. The disorder stems from mutations in ion channels (commonly sodium or calcium channels) that lead to an abnormal shift of potassium into cells during attacks. This results in reduced serum potassium and a transient inability of muscle fibers to depolarize normally. The long exercise test, by repeatedly activating muscle fibers, exposes these abnormal membrane properties through a decrement in compound muscle action potential amplitude. Patients typically experience episodic weakness often triggered by high carbohydrate meals, rest after exercise, or stress. During an attack, the patient is notably weak, and the electrophysiologic testing with a long exercise regimen can demonstrate the hallmark decrement in muscle response. The differential diagnosis includes hyperkalemic periodic paralysis, myotonic disorders, and other neuromuscular junction pathologies like myasthenia gravis. The long exercise test, along with a careful history, serum potassium measurements during attacks, and genetic testing, is crucial in distinguishing hypokalemic periodic paralysis from these entities. Acute management involves cautious potassium supplementation to correct hypokalemia. For prophylaxis, carbonic anhydrase inhibitors such as acetazolamide are commonly used. Lifestyle modifications and avoidance of known triggers are essential. In pregnant or lactating women, potassium supplementation is generally safe; however, careful use and monitoring of acetazolamide are advised since its safety profile requires dose adjustments and close supervision during pregnancy. Option A (Long exercise test) is correct because it demonstrates the characteristic decrement in muscle action potential amplitude in hypokalemic periodic paralysis, making it a useful diagnostic tool. Option B (Short exercise test) is less sensitive for this condition and is typically used in other neuromuscular disorders. 1. Episodic muscle weakness in hypokalemic periodic paralysis is often precipitated by high carbohydrate meals or rest after exercise. 2. The long exercise test is a key diagnostic tool because it reveals the decrement in compound muscle action potentials post-exercise. Recent guidelines emphasize combining electrophysiologic testing with genetic profiling for definitive diagnosis. Ongoing research focuses on improving prophylactic strategies and understanding the molecular basis to develop targeted therapies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "20s male hx of limbs weakness, in examination found to have significant weakness of posterior thigh and scapular muscles and winging of scapula, sparing face. Muscle biopsy showed esinophila\nWhat is the diagnosis:",
    "option_a": "calpin 2A",
    "option_b": "lamin 1B",
    "option_c": "calvin 1C",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Limb-girdle muscular dystrophies (LGMD) are a heterogeneous group of disorders primarily affecting the proximal (shoulder and pelvic) muscles. LGMD type 2A, also known as calpainopathy, is one of the common recessive forms and typically spares the face. LGMD 2A is caused by mutations in the calpain-3 gene, which encodes a muscle-specific protease essential for normal muscle repair and remodeling. The deficiency of calpain-3 leads to progressive muscle fiber degeneration, replacement by fat and fibrous tissue, and a characteristic dystrophic process seen on biopsy. Young adult patients often present with difficulty in activities requiring shoulder and pelvic girdle strength, such as climbing stairs or lifting objects, with scapular winging being a prominent sign. The sparing of facial muscles helps differentiate it from other myopathies like facioscapulohumeral muscular dystrophy. The workup includes a detailed clinical exam, serum creatine kinase measurement (often elevated), muscle biopsy showing dystrophic changes, and confirmation with genetic testing. Differential diagnoses include other LGMD subtypes, congenital myopathies, and inflammatory myopathies. There is no curative treatment; management is supportive and focuses on physical therapy to maintain mobility and strength, occupational therapy, and orthopedic interventions to manage contractures. Cardiac and respiratory function assessments should be done periodically. In pregnant or lactating patients, a carefully adjusted physiotherapy program and close monitoring are recommended to maintain function and ensure safety. Option A (calpin 2A) is correct because it refers to LGMD type 2A (calpainopathy), which matches the clinical presentation of proximal weakness with scapular winging yet sparing of the face. Option B (lamin 1B) is linked with other muscular dystrophies, and Option C (calvin 1C) is not a recognized entity. 1. Calpainopathy (LGMD 2A) commonly presents in young adults with pronounced proximal muscle weakness and scapular winging. 2. Facial muscle sparing is an important clue that helps differentiate it from other muscular dystrophies. Recent advances in molecular genetics have enhanced diagnostic accuracy, and research into gene therapy is underway. Current clinical guidelines stress multidisciplinary management and genetic counseling.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "adult with hx of gait issues\nExamination significant weakness and atrophy of gastrocnemius muscle with mild weakness in upper limbs\nWhat is the diagnosis:",
    "option_a": "dysferlin 2B",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Dysferlinopathy includes a spectrum of muscle disorders resulting from mutations in the dysferlin gene. It can present as either a distal myopathy (Miyoshi myopathy) with predominant calf involvement or as limb-girdle muscular dystrophy (LGMD 2B) with more proximal involvement later in the course. Mutations in the dysferlin gene cause a defective protein responsible for repairing muscle cell membranes. This leads to progressive muscle fiber degeneration and necrosis, particularly affecting the gastrocnemius muscles, with eventual fatty and fibrous replacement. Adults typically present with gait difficulties and pronounced weakness and atrophy of the calf muscles, sometimes accompanied by mild upper limb weakness as the disease advances. The preferential involvement of the gastrocnemius is a key clinical feature of dysferlinopathy. The differential diagnosis includes other distal myopathies, inflammatory myopathies, and other subtypes of LGMD. Diagnosis is supported by elevated creatine kinase levels, electromyography, muscle MRI, and confirmatory genetic testing for dysferlin gene mutations. Management is mainly supportive with physiotherapy, use of assistive devices for mobility, and regular monitoring of muscle strength. There is no definitive cure, though gene therapy and other targeted therapies are under investigation. During pregnancy and lactation, treatment plans should focus on safe physiotherapy regimens and nutritional support to optimize muscle function while monitoring for any complications. Option A (dysferlin 2B) is correct because it denotes the dysferlinopathy variant of LGMD, which aligns well with the clinical findings of predominant gastrocnemius weakness and atrophy. The other options are not provided or are not applicable. 1. Dysferlinopathy, especially in its distal form (Miyoshi myopathy), commonly presents with selective calf muscle weakness and atrophy. 2. Genetic testing is critical for distinguishing dysferlinopathy from other muscular dystrophies. Current research is focused on novel gene therapies and the use of next-generation sequencing for early diagnosis. Multidisciplinary management remains the cornerstone of care, with updated guidelines emphasizing regular functional assessments.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Post bariatric surgery done 6 months back, and symptom started 3 months back came with weakness, imbalance on exam loss of proprioception, spasticity, B12 and melanoic acid normal.",
    "option_a": "Zinc deficiency",
    "option_b": "B12 deficiency",
    "option_c": "Cu deficiency",
    "option_d": "Folate deficiency",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Post bariatric surgery patients are prone to developing micronutrient deficiencies due to altered gastrointestinal anatomy and absorption. Copper deficiency, although less commonly recognized than B12 deficiency, can lead to a myelopathy that mimics subacute combined degeneration. Copper plays a key role in myelin formation and neuronal function. Deficiency leads to demyelination of the dorsal columns and lateral corticospinal tracts, resulting in sensory deficits (especially proprioception loss) and motor abnormalities such as spasticity and weakness. This myelopathy closely resembles the findings seen in vitamin B12 deficiency, but with normal B12 levels. The patient presents with gait disturbance, imbalance, weakness, loss of proprioception, and spasticity. The normal B12 levels help to rule out B12 deficiency and point toward copper deficiency as the underlying cause. Differential diagnoses include vitamin B12 deficiency, folate deficiency, and disorders induced by excess zinc (which can secondarily cause copper deficiency). Confirmation is achieved by measuring serum copper and ceruloplasmin levels, alongside a thorough nutritional history, especially following bariatric surgery. The primary treatment is copper supplementation, which may be given orally or intravenously depending on the severity of the deficiency. In pregnant or lactating patients, supplementation should be carefully tailored and monitored to ensure both maternal and fetal/neonatal safety. Long-term nutritional follow-up is crucial, particularly for post bariatric surgery patients, to prevent recurrence of deficiencies. Option A (Zinc deficiency) is less likely to cause the myelopathic features described. Option B (B12 deficiency) is ruled out by normal laboratory values. Option C (Copper deficiency) is correct, as it closely matches the clinical scenario. Option D (Folate deficiency) does not typically present with neurological deficits. 1. Always consider copper deficiency in post bariatric surgery patients who develop neurological symptoms, even when B12 levels are normal. 2. Nutritional monitoring is essential to prevent trace mineral deficiencies following bariatric procedures. Recent research highlights an increasing incidence of copper deficiency-related myelopathy in bariatric surgery patients. Updated clinical practice guidelines now recommend routine monitoring of trace minerals post-surgery, and early copper supplementation is emphasized to prevent irreversible neurological damage.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]